WFDC3 and pancreatic adenocarcinoma: Although in vitro experiments confirmed WFDC3’s pro-metastatic and immunosuppressive properties, systematic in vivo studies are essential to uncover the underlying mechanisms and assess the therapeutic potential of targeting WFDC3 in immunotherapy-resistant PAAD patients.